This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This KCNQ3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 651-679 amino acids from the C-terminal region of human KCNQ3.
KCNQ3
Reactivity: Human
ELISA, IHC
Host: Rabbit
Polyclonal
unconjugated
Application Notes
For WB starting dilution is: 1:1000
Restrictions
For Research Use only
Format
Liquid
Concentration
0.45 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
KCNQ3
(Potassium Voltage-Gated Channel, KQT-Like Subfamily, Member 3 (KCNQ3))
KCNQ3 antibody, si:ch211-66b9.3 antibody, BFNC2 antibody, EBN2 antibody, KV7.3 antibody, potassium voltage-gated channel subfamily Q member 3 antibody, potassium voltage-gated channel, KQT-like subfamily, member 3 antibody, potassium voltage-gated channel, subfamily Q, member 3 antibody, KCNQ3 antibody, kcnq3 antibody, Kcnq3 antibody
Background
The M channel is a slowly activating and deactivating potassium channel that plays a critical role in the regulation of neuronal excitability. The M channel is formed by the association of the protein encoded by this gene and one of two related proteins encoded by the KCNQ2 and KCNQ5 genes, both integral membrane proteins. M channel currents are inhibited by M1 muscarinic acetylcholine receptors and activated by retigabine, a novel anti-convulsant drug. Defects in this gene are a cause of benign familial neonatal convulsions type 2 (BFNC2), also known as epilepsy, benign neonatal type 2 (EBN2).